FDA Inspection 1019839 — Hongfe Zhang
The FDA completed an inspection of Hongfe Zhang on June 16, 2017 in Beijing. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- June 16, 2017
- Fiscal Year
- 2017
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Beijing (China)
Additional Details
Clinical Investigator (CI)